Genzyme submits MS drug Lemtrada for FDA approval

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eisOCduTtWCfvEzqCidncVCicNrTzK

January 29, 2013 More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how. The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.   Today's Top Story    Genzyme submits MS drug Lemtrada for FDA approval The FDA received Genzyme's application for Lemtrada, or alemtuzumab, as treatment for relapsing multiple sclerosis. The drugmaker says the FDA's decision could come in the second half of the year. Drug Store News (1/28)      Earn American Airlines AAdvantage® miles from your business expenses and enjoy exclusive rewards and benefits • Earn 30,000 American Airlines AAdvantage® bonus miles* • First eligible checked bag is free* • Priority Boarding* • Double AAdvantage® miles on eligible business purchases* *Learn more.   Health Care & Policy  Orexo licenses respiratory program to AstraZeneca Sweden's Orexo granted AstraZeneca the right to carry out further preclinical work and evaluation of compounds in its OX-CLI program targeted for respiratory diseases. AstraZeneca was also given the option to purchase the compounds in the program. The deal entitles Orexo to possible milestone fees and royalties. PharmaTimes (U.K.) (1/25)      BIO picks San Diego for biotech and bioenergy summit BIO, in collaboration with life sciences organization BIOCOM, will hold the 2013 Pacific Rim Summit on Biotechnology and Bioenergy in San Diego. The Dec. 8-11 event will highlight the growth of the industrial biotechnology and bioenergy industries in the Asia-Pacific region and North America. San Diego Business Journal (1/28)      Carmenta gains licensing option for preeclampsia diagnostic tool Carmenta Bioscience has been granted an option to exclusively license technology from Stanford University for undisclosed terms. The Palo Alto, Calif.-based company aims to use the technology to design assays for detecting preeclampsia in pregnant women with or without symptoms of the illness, President and CEO Matthew Cooper said. GenomeWeb Daily News (free registration) (1/25)      Keryx's Zerenex hits main goal in kidney disease trial Keryx Biopharmaceuticals' Zerenex, or ferric citrate, met the primary goal of a late-stage trial by significantly reducing blood phosphate levels in patients with end-stage renal disease on dialysis compared with placebo. The drug also achieved two secondary endpoints of the study. Keryx plans to submit the drug for approval in the U.S. and Europe next quarter. Reuters (1/28)        Company & Financial News  IPO could raise $50M for maker of Humaneered antibodies KaloBios Pharmaceuticals could raise about $50 million from selling 3.85 million shares in an initial public offering. The company specializes in developing Humaneered antibodies, which are human antibodies based on nonhuman antibodies for the treatment of cancer and respiratory diseases. American City Business Journals/San Francisco/BiotechSF blog (1/25)      Colorectal cancer Dx firm obtains $6.7 million A funding round has pulled in $6.7 million for Epigenomics, which has operations in Seattle and Berlin. The funding comes a few weeks after the company completed its premarket approval application with the FDA for Epi proColon, its blood-based assay used to diagnose colorectal cancer. GenomeWeb Daily News (free registration) (1/25)        Global Developments  IMI consortium funds research into drug effectiveness Researchers funded by a consortium of pharmaceutical companies and Europe's Innovative Medicines Initiative are using advanced laser technology to identify how drug molecules interact with protein receptors in order to develop more effective medicines. Scientists at the University of Nottingham in the U.K. are looking at how compounds attach to cells' surface proteins and will explore the relationship between effectiveness and length of time spent bound to the cell. BioOptics World (1/24)      The Buzz(CORPORATE ANNOUNCEMENTS) Hereditary Antithrombin Deficiency and rEVO Biologics' ATryn Appears on TV Segment on Lifetime Morning Show, The Balancing Act(TM) Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com.    Food & Agriculture  Survey: Most Greek farmers are open to adoption of biotech corn Sixty-one percent of farmers in Greece would support growing biotech corn if its cultivation were approved, according to a survey published in the in the Journal of Agribiotechnology Management and Economics. AllAboutFeed.net (1/28)        Industrial & Environmental  Feds set aside $6M for biomass supply chain systems The Department of Energy is allocating $6 million for projects aimed at developing technologies that would facilitate the harvest and delivery of biomass feedstocks to biorefineries. The agency will select two multi-year projects to receive grants. BiomassMagazine.com (1/28)        News from BIO  Ship with FedEx FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.      Learn more about BIO -> Conferences  |  Join BIO  |  Media  |  Issues  |  Industry   SmartQuote  I attribute my success to this: I never gave or took any excuse." --Florence Nightingale, British social reformer, nurse and statistician          This SmartBrief was created for jmabs1@gmail.com   Subscriber Tools       Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy Advertise Account Director:  Meryl Harold (202) 407-7828 Download Media Kit   Read more at SmartBrief.com A powerful website for SmartBrief readers including: Industry Home Readers' Choice Search Archive Grab our News Widget Get this RSS Feed Publish your Press Release Download a SmartBrief Mobile app today       Recent BIO SmartBrief Issues: Monday, January 28, 2013 Friday, January 25, 2013 Thursday, January 24, 2013 Wednesday, January 23, 2013 Tuesday, January 22, 2013     Lead Editor:  Tom Parks       Mailing Address: SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004     © 1999-2013 SmartBrief, Inc.® Legal Information